Anticipated $3.35 EPS for Allergan plc (AGN) on May, 8

April 16, 2018 - By Russell Jones

Allergan plc (NYSE:AGN) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.25. That’s change of 0.92, from 2017Q3’s 0.33. 2 investors sold all, 2 reduced holdings as Allergan plc ratio increased. 4 grew positions while 1 funds amassed positions. Funds hold 44,210 shares thus 18.56% less from 2017Q3’s 54,287 shares.
Gemmer Asset Mgmt Ltd Liability Company reported 214 shs or 0.01% of all its holdings. Mitchell Mcleod Pugh And Williams holds 3,965 shs or 0.45% of its capital. Grassi Inv reported 0.2% in Allergan plc (NYSE:AGN). Callahan Advsr Limited Liability Company reported 4,500 shs. Cubic Asset Management Ltd Limited Liability Company accumulated 2,321 shs. Eqis Mgmt Incorporated reported 10,789 shs. 14,953 were accumulated by Frontier Inv Management. Rech Management invested in 0% or 33 shs.

On May, 8 Allergan plc (NYSE:AGN)’s earnings report is expected by WallStreet, as reported by Faxor. Analysts have expectation on stock’s EPS of $3.35. That’s 0.00 % from last year’s $3.35 EPS. In case of $3.35 EPS AGN’s profit could hit $1.10 billion. -31.07 % negative EPS growth is what analysts predict. $4.86 EPS was published for last [previous quarter]. On during the last trading session the stock increased $2.08 or 1.27%, reaching $166.45.Allergan plc has volume of 1.75M shares. Since April 16, 2017 AGN has declined 33.03% and is downtrending. The stock underperformed the S&P 500 by 44.58%.

Allergan plc (NYSE:AGN) Ratings Coverage

Total analysts of 17 have positions in Allergan plc Ordinary Shares (NYSE:AGN) as follows: 12 rated it a “Buy”, 0 with “Sell” and 5 with “Hold”. The positive are 71%. Since October 17, 2017 according to StockzIntelligence Inc Allergan plc Ordinary Shares has 33 analyst reports. On Thursday, November 2 RBC Capital Markets maintained Allergan plc (NYSE:AGN) with “Buy” rating. On Thursday, January 4 the stock of Allergan plc (NYSE:AGN) has “Buy” rating given by RBC Capital Markets. In Thursday, November 2 report Wells Fargo maintained the stock with “Buy” rating. On Wednesday, November 29 the rating was upgraded by Morgan Stanley to “Overweight”. In Wednesday, November 1 report Mizuho maintained the stock with “Hold” rating. The company rating was maintained by Morgan Stanley on Wednesday, December 6. In Monday, January 29 report Barclays Capital upgraded the stock to “Overweight” rating. The company rating was maintained by Wells Fargo on Wednesday, December 6. On Wednesday, February 7 the firm has “Buy” rating given by Bank of America. On Tuesday, October 17 the firm has “Buy” rating given by Credit Suisse.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide.The firm is worth $54.53 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions.Currently it has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women??s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer??s disease.

Allergan plc (NYSE:AGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.